Residency · Residency · Medicine Pediatrics

Inflammatory Bowel Disease: Pediatric Onset and Lifelong Management

Overview

Up to 25% of inflammatory bowel disease (IBD) presents before age 18. Pediatric-onset IBD tends to be more extensive, more aggressive, and more likely to require early immunomodulation or biologic therapy. Growth failure and pubertal delay add unique pediatric dimensions. The Med-Peds physician must understand the differences in disease behavior, management philosophy, and transition challenges between pediatric and adult IBD care.

Classification

Crohn Disease (CD)

Can affect any part of the GI tract (mouth to anus); skip lesions; transmural inflammation. Montreal classification (location): L1 ileal, L2 colonic, L3 ileocolonic, L4 upper GI (modifier) Montreal classification (behavior): B1 non-stricturing/non-penetrating, B2 stricturing, B3 penetrating; p perianal modifier. Paris classification (pediatric modification): adds L4a (proximal to ligament of Treitz) and L4b (distal small bowel), and growth impairment (G0/G1)

Ulcerative Colitis (UC)

Limited to colon and rectum; continuous inflammation; mucosal/submucosal involvement. Montreal classification (extent): E1 proctitis, E2 left-sided, E3 pancolitis. Pediatric UC is more likely to present with pancolitis (E3) -- approximately 60-80% vs. 30-40% in adults.

IBD-Unclassified (IBD-U)

10-15% of pediatric IBD; features of both CD and UC without clear distinction. More common in young children (<6 years)

Epidemiology

Pediatric IBD incidence: approximately 10 per 100,000 children/year (rising globally) Bimodal age distribution of IBD: peak at 15-30 years (adolescents/young adults) and 50-70 years. Very early onset IBD (<6 years): consider monogenic forms (IL-10 receptor deficiency, XIAP deficiency, CGD) Geographic variation: highest in North America and Northern Europe; rapidly increasing in Asia.

Clinical Presentation

Pediatric IBD

Crohn disease: abdominal pain (often right lower quadrant), diarrhea (may be non-bloody), weight loss, growth failure (may be the ONLY presenting sign), fatigue, perianal disease (fistulae, tags, abscesses), oral aphthous ulcers, fever. Ulcerative colitis: bloody diarrhea, urgency, tenesmus, abdominal cramping, occasionally toxic megacolon at presentation. Growth failure: linear growth deceleration, delayed bone age, pubertal delay; may precede GI symptoms by months to years. Mechanism: chronic inflammation (IL-6, TNF-alpha suppress IGF-1), inadequate nutrition, corticosteroid effects. Screening: plot height velocity on growth chart at every visit; compare to mid-parental height. Extraintestinal manifestations: occur in 25-35% of pediatric IBD. Musculoskeletal: arthritis (most common EIM), sacroiliitis. Dermatologic: erythema nodosum, pyoderma gangrenosum. Ophthalmologic: uveitis, episcleritis. Hepatobiliary: primary sclerosing cholangitis (more common in pediatric UC) Hematologic: anemia (iron deficiency + anemia of chronic disease), VTE risk.

Adult IBD

Similar GI symptoms but growth is not a concern. Extraintestinal manifestations same spectrum. Higher rates of stricturing and penetrating Crohn disease at diagnosis (may reflect delayed diagnosis or age-related disease progression) Greater burden of comorbidities (cardiovascular, metabolic) affecting treatment decisions.

Diagnosis

Laboratory

CBC: anemia (iron deficiency, B12/folate in ileal CD), thrombocytosis. CRP and ESR: elevated in active inflammation; CRP more specific. Albumin: low in severe disease (malnutrition and protein-losing enteropathy) Fecal calprotectin: excellent non-invasive marker of intestinal inflammation; levels >250 mcg/g highly suggestive of IBD; useful for monitoring and distinguishing IBD from IBS. Celiac serology: to exclude celiac disease (mimics IBD) Stool studies: C. difficile, enteric pathogens (to exclude infectious causes)

Endoscopy

Upper and lower endoscopy with biopsies: gold standard for diagnosis in both children and adults. Pediatric-specific: upper endoscopy should be performed in ALL children with suspected IBD (higher rate of upper GI Crohn involvement) Histology: granulomas (pathognomonic but present in only 30-50% of CD), crypt distortion, chronic inflammation.

Imaging

MR Enterography (MRE): preferred cross-sectional imaging (no radiation); evaluates small bowel inflammation, strictures, fistulae, abscesses. Wireless capsule endoscopy: small bowel visualization when MRE is equivocal; patency capsule first if stricture suspected. CT enterography: adults when MRI not available; avoid in children due to radiation. Pelvic MRI: perianal Crohn disease assessment.

Disease Activity Assessment

Pediatric CD Activity Index (PCDAI): validated for children <18; scores based on symptoms, exam, labs, growth. Pediatric UC Activity Index (PUCAI): symptom-based scoring; remission <10, mild 10-34, moderate 35-64, severe >=65. Adult: CDAI (Crohn Disease Activity Index), Mayo score (UC), Harvey-Bradshaw Index (simplified CD) Mucosal healing: increasingly the treatment target; endoscopic remission (SES-CD <3 for CD, Mayo endoscopic subscore 0-1 for UC)

Management

Treatment Goals

Induce and maintain clinical and endoscopic remission (mucosal healing); Restore and maintain normal growth and development in children; Minimize corticosteroid exposure; Prevent complications (strictures, fistulae, colorectal cancer); Optimize quality of life and psychosocial functioning.

Induction Therapy

Corticosteroids

Prednisone/prednisolone: 1-2 mg/kg/day (max 40-60 mg) for moderate-severe flares; taper over 8-12 weeks. Budesonide (enteric-coated): for mild-moderate ileal/right-sided Crohn disease; less systemic side effects. IV methylprednisolone: for severe/fulminant disease (hospitalized patients) Corticosteroids are INDUCTION only -- never maintenance; growth suppression in children is a critical concern.

Exclusive Enteral Nutrition (EEN)

First-line induction therapy for pediatric Crohn disease in many centers (ECCO/ESPGHAN guidelines) Polymeric formula delivered orally or via NG tube for 6-8 weeks as sole nutrition source. Equivalent efficacy to corticosteroids for inducing remission WITHOUT steroid side effects. Promotes mucosal healing and improves nutrition/growth. Underutilized in North America compared to Europe/Australia/Japan. Not effective for UC.

Maintenance Therapy

5-ASA (Mesalamine)

Mild UC: first-line maintenance. No role in Crohn disease maintenance (SONIC trial demonstrated inferiority) Formulations: oral (Asacol, Lialda, Pentasa) and rectal (suppositories, enemas for proctitis/left-sided UC)

Thiopurines (Azathioprine, 6-Mercaptopurine)

Historically mainstay of maintenance therapy. TPMT/NUDT15 genotyping: MUST check before starting (homozygous deficiency causes severe myelosuppression) Monitoring: CBC q3 months, LFTs. Risks: lymphoma (hepatosplenic T-cell lymphoma -- rare but fatal, especially in young males on thiopurine + anti-TNF), non-melanoma skin cancer, infections. Increasingly being supplanted by earlier biologic therapy.

Methotrexate

Crohn disease maintenance (not UC); 15 mg/m2 subcutaneous weekly (pediatric); 25 mg SC weekly (adult); Requires folic acid supplementation; monitor CBC and LFTs; Teratogenic -- strict contraception required.

Biologic Therapies

Top-Down vs. Step-Up

Step-up: traditional approach; start with 5-ASA or steroids, escalate to immunomodulators, then biologics. Top-down: early biologic (anti-TNF) + immunomodulator; evidence from SONIC trial (adults) and pediatric studies shows higher mucosal healing rates. Top-down increasingly favored in pediatric CD, especially with high-risk features (deep ulcers, extensive disease, perianal disease, growth failure, severe presentation)

Surgical Management

Crohn disease: surgery is NOT curative; reserved for complications (stricture, abscess, fistula refractory to medical therapy); ileocecal resection for localized disease. Ulcerative colitis: total proctocolectomy with ileal pouch-anal anastomosis (IPAA) is curative; indicated for refractory disease, toxic megacolon, dysplasia/cancer. Pediatric surgical considerations: staged procedures, growth implications, quality of life with ileostomy/pouch.

Monitoring and Surveillance

Regular assessment with fecal calprotectin (non-invasive), CRP, CBC, albumin. Periodic endoscopy: mucosal healing assessment; colonoscopic surveillance for dysplasia starting 8 years after diagnosis (UC and Crohn colitis) Drug level monitoring: trough levels and anti-drug antibodies for anti-TNF agents (therapeutic drug monitoring or TDM) Growth monitoring: height velocity, bone age, pubertal staging (Tanner) at every visit in children. Bone density: DXA scan if chronic steroid exposure or other risk factors. Vaccinations: ensure up-to-date BEFORE starting immunosuppression; avoid live vaccines while on immunosuppressive therapy.

<image>A comprehensive comparison diagram showing pediatric versus adult IBD characteristics. Two parallel columns display differences in: disease extent at diagnosis (pediatric UC more likely pancolitis, pediatric CD more extensive), unique pediatric features (growth failure, pubertal delay, very early onset forms), treatment philosophy (EEN as first-line induction for pediatric CD, top-down approach increasingly favored), and monitoring priorities (growth velocity charts in children, colonoscopic surveillance in both). A central overlap zone shows shared features and medications used across ages.</image>

<image>A treatment algorithm for pediatric Crohn disease showing the decision pathway from diagnosis through management. Starting with disease severity and phenotype assessment, the flowchart branches to: mild disease (EEN or budesonide for ileal), moderate disease (EEN or corticosteroids for induction, then thiopurine or methotrexate for maintenance), and severe/high-risk disease (top-down approach with anti-TNF plus immunomodulator, with EEN as bridge). Response assessment at 8-12 weeks leads to continuation, dose optimization via TDM, or switch to alternative biologic class. Growth velocity is shown as a parallel monitoring track throughout.</image>

<image>An infographic illustrating the concept of growth failure as a presenting sign of pediatric IBD. A growth chart shows a child's height trajectory declining from the 50th percentile to below the 5th percentile over 2 years before GI symptoms develop. Alongside, the mechanisms are shown: TNF-alpha and IL-6 suppressing IGF-1 and growth hormone signaling at the growth plate, inadequate caloric intake, and corticosteroid-mediated growth suppression. The bottom section shows growth recovery after effective anti-TNF therapy with catch-up growth trajectory.</image>

Clinical Pearls

Growth failure may be the ONLY presenting sign of pediatric Crohn disease -- plot height velocity at every visit and investigate any deceleration. Pediatric UC presents with pancolitis in 60-80% of cases (vs. 30-40% in adults), reflecting more aggressive disease biology. Exclusive enteral nutrition is as effective as corticosteroids for inducing remission in pediatric Crohn disease without steroid side effects -- it is first-line per ECCO/ESPGHAN guidelines. ALWAYS check TPMT/NUDT15 genotype before starting azathioprine or 6-MP -- homozygous deficiency causes life-threatening myelosuppression. Top-down therapy with early biologic use is increasingly favored for high-risk pediatric Crohn disease to prevent complications and promote mucosal healing. Fecal calprotectin is an excellent non-invasive marker for monitoring disease activity and predicting relapse -- use it liberally. Ensure all vaccinations (especially live vaccines) are up-to-date BEFORE initiating immunosuppressive therapy. Therapeutic drug monitoring (TDM) for anti-TNF agents improves outcomes by identifying subtherapeutic levels and anti-drug antibodies early.

References

• Rosen MJ, Dhawan A, Saeed SA. Inflammatory bowel disease in children and adolescents. JAMA Pediatr. 2015;169(11):1053-1060.
• Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn disease. J Crohns Colitis. 2014;8(10):1179-1207.
• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn disease (SONIC trial). N Engl J Med. 2010;362(15):1383-1395.
• Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of paediatric ulcerative colitis (ECCO/ESPGHAN 2018 guidelines). J Crohns Colitis. 2018;12(12):1517-1531.
• Levine A, Wine E, Assa A, et al. Crohn disease exclusion diet plus partial enteral nutrition induces sustained remission in a randomized controlled trial. Gastroenterology. 2019;157(2):440-450.

Read this lecture as Markdown